Sodium‐glucose cotransporter 2 inhibitor luseogliflozin improves glycaemic control, assessed by continuous glucose monitoring, even on a low‐carbohydrate diet

Ítems similars

• Effects of luseogliflozin, a sodium–glucose co‐transporter 2 inhibitor, on 24‐h glucose variability assessed by continuous glucose monitoring in Japanese patients with type 2 diabetes mellitus: a randomized, double‐blind, placebo‐controlled, crossover study
  per: Nishimura, R., et al.
  Publicat: (2015)
• Impact of Reduced Renal Function on the Glucose-Lowering Effects of Luseogliflozin, a Selective SGLT2 Inhibitor, Assessed by Continuous Glucose Monitoring in Japanese Patients with Type 2 Diabetes Mellitus
  per: Jinnouchi, Hideaki, et al.
  Publicat: (2016)
• Sodium-glucose cotransporter inhibitors: beyond glycaemic control
  per: Vergara, Ander, et al.
  Publicat: (2019)
• Absence of Drug–Drug Interactions Between Luseogliflozin, a Sodium–Glucose Co-transporter-2 Inhibitor, and Various Oral Antidiabetic Drugs in Healthy Japanese Males
  per: Sasaki, Takashi, et al.
  Publicat: (2015)
• Sodium-Glucose Cotransporter-2 Inhibitor-Induced Euglycemic Diabetic Ketoacidosis Followed by Excessively Low Carbohydrate Diet
  per: Tsutsui, Erika, et al.
  Publicat: (2021)